載入中
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
前收盤價
US$3.32
+US$0.12 · +3.75%
盤中時間採用ET。市場資料可能有所延遲。
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
日內區間
目前US$3.32
52週區間
目前US$3.32
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
57
合理估值
情緒
44
多空交錯
風險
69
高風險
動能
30
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
日內區間
目前US$3.32
52週區間
目前US$3.32
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 70.59萬 USD | 46.43萬 USD | 22.62萬 USD | 25.54萬 USD | 72.27萬 USD |
| 銷貨成本 | 2720 USD | 4822 USD | 3.15萬 USD | 7.18萬 USD | 17.53萬 USD |
| 毛利 | 70.32萬 USD | 45.95萬 USD | 19.47萬 USD | 18.36萬 USD | 54.74萬 USD |
| 研究與開發 | 823.88萬 USD | 236.06萬 USD | 366.67萬 USD | 184.27萬 USD | 126.29萬 USD |
| 銷售、一般及管理費用 | 434.52萬 USD | 385.2萬 USD | 306.2萬 USD | 495.99萬 USD | 497.13萬 USD |
| 營業費用 | 1258.39萬 USD | 621.26萬 USD | 672.87萬 USD | 680.26萬 USD | 623.42萬 USD |
| 利息收入 | 3017 USD | 1.43萬 USD | 4.32萬 USD | — | — |
| 折舊和攤銷 | 8.78萬 USD | 7.62萬 USD | 14.54萬 USD | 10.27萬 USD | 14.76萬 USD |
| 營業利益 | −1188.07萬 USD | −575.31萬 USD | −653.4萬 USD | −661.9萬 USD | −568.69萬 USD |
| 淨利 | −1190.18萬 USD | −579.53萬 USD | −666.49萬 USD | −726.93萬 USD | −402.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$1.50
下跌空間 54.82%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月3日 | 1:15 | — | — |
股票分割 | 2021年1月12日 | 1:30 | — | — |
股票分割 | 2015年12月16日 | 11:10 | — | — |
股票分割 | 2009年6月30日 | 1:4 | — | — |
已生效 2026年8月3日
1:15
已生效 2021年1月12日
1:30
已生效 2015年12月16日
11:10
已生效 2009年6月30日
1:4
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
